Endologix (ELGX) Posts Q1 Loss of $0.90/Share

Endologix (NASDAQ: ELGX) reported Q1 EPS of ($0.90), which does not compare to the analyst estimate of ($0.61). Revenue for the quarter came in at $28.5 million versus the consensus estimate of $29.7 million.

“Our first quarter results were impacted by the deferral of AAA procedures related to the COVID-19 pandemic,” commented John Onopchenko, Chief Executive Officer of Endologix, Inc. “We are confident that these deferred procedures will be rescheduled once hospitals widen the criteria for treating AAA patients from today's 'emergent only' standard. As we navigate this pandemic, our top priority remains the safety of our employees as well as the patients, surgeons, and affiliated caregivers that we serve. As hospitals resume a more normalized level of care, we are also focused on ensuring the continued availability of products to patients in need. We are taking the necessary actions to prepare for a return to pre-pandemic procedure volume and to provide necessary case support and ongoing execution of our continuous improvement mandate.”

For earnings history and earnings-related data on Endologix (ELGX) click here.

You May Also Be Interested In

• Investing.com’s stocks of the week
• inTEST Corp (INTT) reported Q2 Revenue ; Offers Guidance
• Regency Centers (REG) Tops Q2 EPS by 2c